What is the intrinsic value of LMNL?
As of 2025-06-02, the Intrinsic Value of Liminal BioSciences Inc (LMNL) is
0.52 USD. This LMNL valuation is based on the model Peter Lynch Fair Value.
With the current market price of 8.50 USD, the upside of Liminal BioSciences Inc is
-93.90%.
Is LMNL undervalued or overvalued?
Based on its market price of 8.50 USD and our intrinsic valuation, Liminal BioSciences Inc (LMNL) is overvalued by 93.90%.
LMNL Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(369.42) - (124.86) |
(184.18) |
-2266.8% |
| DCF (Growth 10y) |
(126.05) - (339.46) |
(178.26) |
-2197.2% |
| DCF (EBITDA 5y) |
(49.93) - (65.94) |
(898.93) |
-123450.0% |
| DCF (EBITDA 10y) |
(70.00) - (88.99) |
(898.93) |
-123450.0% |
| Fair Value |
0.52 - 0.52 |
0.52 |
-93.90% |
| P/E |
8.50 - 8.50 |
8.50 |
-0.0% |
| EV/EBITDA |
(94.02) - (36.92) |
(74.31) |
-974.3% |
| EPV |
(132.58) - (174.42) |
(153.50) |
-1905.9% |
| DDM - Stable |
1.18 - 4.68 |
2.93 |
-65.5% |
| DDM - Multi |
(85.88) - (265.01) |
(129.79) |
-1626.9% |
LMNL Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
27.62 |
| Beta |
0.66 |
| Outstanding shares (mil) |
3.25 |
| Enterprise Value (mil) |
14.45 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.05% |
| Cost of Debt |
6.25% |
| WACC |
7.98% |